WEE1 and acute lymphoblastic leukemia: Its efficacy is better documented in association with other molecules, such as blinatumomab and the WEE1 inhibitor AZD-1775, in patients with relapsed/refractory Ph+ disease and in T-ALL cell lines [158,159,160].